Mr William Scott Mandel, MD | |
82-6123 Mamalahoa Hwy, Top Floor, Captain Cook, HI 96704-8203 | |
(808) 323-8200 | |
(808) 323-8400 |
Full Name | Mr William Scott Mandel |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 82-6123 Mamalahoa Hwy, Captain Cook, Hawaii |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699873992 | NPI | - | NPPES |
01159301 | Medicaid | HI | |
C1212-4 | Other | HI | HMSA PROVIDER NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 3644 (Hawaii) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr William Scott Mandel, MD Po Box 202, Captain Cook, HI 96704-0202 Ph: (808) 323-8200 | Mr William Scott Mandel, MD 82-6123 Mamalahoa Hwy, Top Floor, Captain Cook, HI 96704-8203 Ph: (808) 323-8200 |
News Archive
ResCare, Inc. announced today that it has entered into a definitive agreement with an entity sponsored by Onex Partners III, L.P. ("Onex"), an affiliate of Onex Corporation. Under the terms of the agreement, Onex would acquire all of the outstanding shares of ResCare common stock not owned by Onex affiliates or participating members of ResCare's management for $13.25 per share in cash, which represents a 30.7% premium to the closing price on August 13, 2010, the last trading day before Onex made its initial proposal.
Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.
The rise of continuous blood glucose monitor and insulin pump technologies has lessened the intricate task of monitoring and regulating blood glucose levels for people with diabetes, but improvements to these devices could still significantly improve lives.
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).
› Verified 8 days ago